| Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results DF Martin, MG Maguire, SL Fine, G Ying, GJ Jaffe, JE Grunwald, C Toth, ... Ophthalmology 119 (7), 1388-1398, 2012 | 1972 | 2012 |
| Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR study DM Brown, M Michels, PK Kaiser, JS Heier, JP Sy, T Ianchulev Ophthalmology 116 (1), 57-65. e5, 2009 | 1732 | 2009 |
| Diabetic retinopathy and diabetic macular edema: pathophysiology, screening, and novel therapies TA Ciulla, AG Amador, B Zinman Diabetes care 26 (9), 2653-2664, 2003 | 1215 | 2003 |
| Ranibizumab for macular edema following branch retinal vein occlusion: six-month primary end point results of a phase III study PA Campochiaro, JS Heier, L Feiner, S Gray, N Saroj, AC Rundle, ... Ophthalmology 117 (6), 1102-1112. e1, 2010 | 1188 | 2010 |
| Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III study DM Brown, PA Campochiaro, RP Singh, Z Li, S Gray, N Saroj, AC Rundle, ... Ophthalmology 117 (6), 1124-1133. e1, 2010 | 1074 | 2010 |
| Vascular endothelial growth factor–induced retinal permeability is mediated by protein kinase C in vivo and suppressed by an orally effective β-isoform–selective inhibitor LP Aiello, SE Bursell, A Clermont, E Duh, H Ishii, C Takagi, F Mori, ... Diabetes 46 (9), 1473-1480, 1997 | 936 | 1997 |
| Two-year outcomes of the ranibizumab for edema of the mAcula in diabetes (READ-2) study QD Nguyen, SM Shah, AA Khwaja, R Channa, E Hatef, DV Do, D Boyer, ... Ophthalmology 117 (11), 2146-2151, 2010 | 771 | 2010 |
| Bacterial endophthalmitis prophylaxis for cataract surgery: an evidence-based update TA Ciulla, MB Starr, S Masket Ophthalmology 109 (1), 13-24, 2002 | 730 | 2002 |
| Enzymatic vitreolysis with ocriplasmin for vitreomacular traction and macular holes P Stalmans, MS Benz, A Gandorfer, A Kampik, A Girach, S Pakola, ... New England Journal of Medicine 367 (7), 606-615, 2012 | 711 | 2012 |
| A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with standard care to treat vision loss associated with macular Edema secondary to branch … IU Scott, MS Ip, PC VanVeldhuisen, NL Oden, BA Blodi, M Fisher, ... Archives of ophthalmology 127 (9), 1115, 2009 | 688 | 2009 |
| A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with observation to treat vision loss associated with macular edema secondary to central … MS Ip, IU Scott, PC VanVeldhuisen, NL Oden, BA Blodi, M Fisher, ... Archives of ophthalmology 127 (9), 1101, 2009 | 661 | 2009 |
| Intravitreal triamcinolone acetonide in exudative age-related macular degeneration RP Danis, TA Ciulla, LM Pratt, W Anliker Retina 20 (3), 244-250, 2000 | 658 | 2000 |
| Twelve-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration BG Busbee, AC Ho, DM Brown, JS Heier, IJ Suñer, Z Li, RG Rubio, P Lai, ... Ophthalmology 120 (5), 1046-1056, 2013 | 583 | 2013 |
| Ranibizumab and bevacizumab for neovascular age-related macular degeneration CATT Research Group New England Journal of Medicine 364 (20), 1897-1908, 2011 | 528 | 2011 |
| Ranibizumab for treatment of neovascular age-related macular degeneration: a phase I/II multicenter, controlled, multidose study JS Heier, AN Antoszyk, PR Pavan, SR Leff, PJ Rosenfeld, TA Ciulla, ... Ophthalmology 113 (4), 633-642. e4, 2006 | 527 | 2006 |
| Primary End Point (Six Months) Results of the Ranibizumab for Edema of the mAcula in diabetes (READ-2) study QD Nguyen, SM Shah, JS Heier, DV Do, J Lim, D Boyer, P Abraham, ... Ophthalmology 116 (11), 2175-2181. e1, 2009 | 503 | 2009 |
| Long-term benefit of sustained-delivery fluocinolone acetonide vitreous inserts for diabetic macular edema PA Campochiaro, DM Brown, A Pearson, T Ciulla, D Boyer, FG Holz, ... Ophthalmology 118 (4), 626-635. e2, 2011 | 482 | 2011 |
| Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration: year 1 results of the FOCUS Study JS Heier, DS Boyer, TA Ciulla, PJ Ferrone, JM Jumper, RC Gentile, ... Archives of Ophthalmology 124 (11), 1532-1542, 2006 | 398 | 2006 |
| A susceptibility locus for multiple sclerosis is linked to the T cell receptor β chain complex E Seboun, MA Robinson, TH Doolittle, TA Ciulla, TJ Kindt, SL Hauser Cell 57 (7), 1095-1100, 1989 | 291 | 1989 |
| Macular morphology and visual acuity in the comparison of age-related macular degeneration treatments trials GJ Jaffe, DF Martin, CA Toth, E Daniel, MG Maguire, GS Ying, ... Ophthalmology 120 (9), 1860-1870, 2013 | 281 | 2013 |
Alon HarrisIcahn School of Medicine at Mount Sinai在 mssm.edu 的电子邮件经过验证
